Protocolo de tratamiento de la diarrea asociada a antibióticos

  1. Carmona-Torre, F.
  2. Yuste, Jose Ramon
  3. del Pozo, J.L.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2018

Issue Title: Enfermedades infecciosas (III) Infecciones por bacilos Gram negativos

Series: 12

Issue: 51

Pages: 3031-3035

Type: Article

DOI: 10.1016/J.MED.2018.03.005 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

The availability and increasingly widespread use of broad-spectrum antibiotic treatments have led to the development of adverse events related to its use, highlighting due to its high frequency the occurrence of diarrhoea. Clostridium difficile infection represents the most common identifiable and treatable aetiology, not forgetting the ability of other pathogens to cause a similar clinical presentation. This form of presentation and the clinical evolution of the affected patients will define the therapeutic options available based on the latest clinical guidelines.

Bibliographic References

  • Cote GA, Buchman AL. Antibiotic associated diarrhoea. Expert Opin Drug Saf. 2006;5(3):361-72.
  • McFarland LV. Antibiotic associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563-78.
  • Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical M, Infectious D. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 Suppl 2:1-26.
  • Hocquart M, Lagier JC, Cassir N, Saidani N, Eldin C, Kerbaj J. Early faecal microbiota transplantation improves survival in severe Clostridium difficile infections. Clin Infect Dis. En prensa 2017.
  • Gergely Szabo B, Kadar B, Szidonia Lenart K, Dezsenyi B, Kunovszki P, Fried K. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect. 2016;22(12):990-5.
  • Martin J, Wilcox M. New and emerging therapies for Clostrid-ium difficile infection. Curr Opin Infect Dis. 2016; 29(6):546-54.
  • Guery B, Menichetti F, Anttila V-J, Adomakoh N, Aguado JM, Bisnauthsing K. Extended pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EX-TEND): a randomised, controlled, open label, phase 3b/4 trial. Lancet Infect Dis. En prensa 2017
Data source: Dialnet